Hollencrest Capital Management Sells 181 Shares of ICON Public Limited (NASDAQ:ICLR)

Hollencrest Capital Management lowered its position in ICON Public Limited (NASDAQ:ICLR) by 49.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 182 shares of the medical research company’s stock after selling 181 shares during the quarter. Hollencrest Capital Management’s holdings in ICON Public were worth $38,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Sierra Ocean LLC acquired a new stake in ICON Public in the 4th quarter valued at $29,000. Park Place Capital Corp lifted its position in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after buying an additional 166 shares in the last quarter. Private Trust Co. NA boosted its holdings in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after buying an additional 82 shares during the last quarter. GAMMA Investing LLC grew its position in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. Finally, First Horizon Advisors Inc. increased its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICON Public stock opened at $183.39 on Thursday. The company’s fifty day simple moving average is $197.41 and its two-hundred day simple moving average is $233.01. ICON Public Limited has a 12-month low of $174.93 and a 12-month high of $347.72. The firm has a market cap of $14.81 billion, a PE ratio of 19.24, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. As a group, equities analysts expect that ICON Public Limited will post 13.38 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on ICLR. Royal Bank of Canada reaffirmed an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a report on Wednesday, January 15th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. JPMorgan Chase & Co. lowered their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Truist Financial dropped their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Citigroup cut their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $279.17.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.